1. Review the epidemiology of peritoneal mesothelioma

2.Review the role of environmental risk,

3. Our evolving understanding of cancer predisposition syndromes in malignant mesothelioma


1.  Review the historical literature of adjuvant chemotherapy in resectable NSCLC

2. Discuss the current and future roles of targeted therapy in the adjuvant setting

3. Address the future directions of peri-operative therapy in NSCLC.


Session date: 
10/31/2016 - 12:00pm to 1:00pm CDT
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Anu Neerukonda and Michael Jelinek, M.D.